According to Goldstein Research, Global anti-diabetic drugs market is expected to reach USD106.5 billion by the end of 2024, growing at a CAGR of 10.12% over the forecast period, 2016-2024. The anti-diabetic promotions by government and other private bodies are increasing the awareness among people, which is driving the growth of market. Global anti-diabetic drugs market segmentation has beendoneon the basis of drug class, mode of administration, diabetes type, drug type and geography. Branded drugs dominate the global anti-diabetic drugs market, with 51% market share. But over the forecast period, generic drugs are expected to dominate the market share. Global anti-diabetic drugs market is dominated by North America having 35% market share in 2016. North America is closely followed by Asia-Pacific, which is growing at a CAGR of 11.2% over the forecast period. Middle East and Africa region is considered to be the opportunistic market for the growth of anti-diabetic drugs in future.
Market Segmentation
On the basis of our in-depth analysis, GlobalAnti-Diabetic DrugsMarket can be segmented as follows:
• By Drug Class
o Biguanides (metformin)
o Sulfonylureas (glimepiride)
o Meglitinides (repaglinide)
o Thiazolidinediones (pioglitazone)
o Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin)
o α-Glucosidase inhibitors (acarbose)
• By Mode of Administration
o Oral (eg. oral hypoglycemic)
o Intravenously (eg. insulin and GLP-1 receptor agonists)
• By Diabetes Type
o Diabetes Type 1
o Diabetes Type 2
o Other Types
o Genetic defects of the β-cell
o Genetic defects in insulin action
o Endocrinopathies
o Drug- or chemical-induced diabetes
o Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)
• By Drug Type
o Generic
o Branded
• On the basis of region
o North America (US, Canada) {Market Share (%), Market Size (USD Billion, Adoption Rate (%)}
o Europe (UK, France, Italy, Germany, Spain, Hungary, Sweden, Russia, Poland and Rest of Europe) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
o Middle East and Africa (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
o Latin America (Brazil, Mexico and Rest of Latin America) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
o Asia Pacific (China, Japan, India, Singapore, South Korea, Australia, New Zealand and Rest of Asia-Pacific) {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
o Rest of the World {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}

“Global Anti-Diabetic Drugs Industry Anmalysis” contains detailed overview of the Global anti-diabetic drugs market. On the basis of our in-depth analysis, market can be segmented in terms of market segmentation by drug class, mode of administration, diabetes type and drug type.
Further, for the in-depth analysis, Global Anti-Diabetic Drugs Market Report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis. This market report also includes competitive outlook of some of the major players profiling of companies such asZydus Cadila, Actavis, Alphapharm, Andromeda Biotech, Arisaph, Astellas Pharma, AstraZeneca, Bayer, Biocon, Blue Cross, Bristol-Myers Squibb, Biogen Idec, Boehringer Ingelheim, Boston Therapeutics, Eli Lilly, Franco-Indian Pharmaceuticals, Furiex Pharmaceuticals, Genentech, Generex Biotechnology Corporation, GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Lupin, Merck & Co., Mylan, Novartis, Novo Nordisk, Pfizer, Ranbaxy Laboratories, Roche, Sanofi, Sun Pharma,etc. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments. Overall, the report represents the Globalanti-diabetic drugs market trends along with market forecast that will help industry consultants, technology providers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Send us sample request @ https://www.goldsteinresearch.com/request-sample/global-antidiabetic-drugs-market-analysis

About Goldstein Research
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Our market research reports provide in-depth analysis of Global and regional variations along with competitors’ overview. Our analysts working on healthcare reports to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.
Contact us for more details
Steve Blade
(Global Sales Head)
USA: + 1-646-568-7747
Canada: 1-437-886-1181
UK: +44-203-318-6627
[email protected]
www.goldsteinresearch.com